Last reviewed · How we verify
Remodulin
At a glance
| Generic name | Remodulin |
|---|---|
| Also known as | Treprostinil Injection, Treprostinil, treprostinil, tyvaso |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open Label Treprostinil Raynaud's Study (PHASE4)
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (PHASE3)
- Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD (PHASE2)
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (PHASE3)
- Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (PHASE2)
- DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study (NA)
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remodulin CI brief — competitive landscape report
- Remodulin updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI